South Africa SAHPRA GMP Audit-Readiness Rubric — Regscribe v0

(Medicines and Related Substances Act, 1965 (Act 101 of 1965) + SAHPRA's Guidelines to Good Manufacturing Practice for Medicines, adopting the PIC/S GMP Guide)

Scope boundary — read this before scoring anything. South Africa's drug GMP framework is structurally unlike the EU/US/Japan/China rubrics already in this project, and this is the single most important thing to understand before applying this rubric:

SAHPRA does not maintain its own substantive GMP chapter text. Since Version 6 (December 2017) of its own guideline, SAHPRA deleted its previously-standalone Chapters 1–9 and Annexes 1–15/17–20 and now works by wholesale incorporation by reference of the PIC/S Guide to GMP (PE 009, currently PE 009-17) — confirmed verbatim in the document's own history table: "Deletion of Chapters 1 – 9, Annexes 1 – 15 and 17 – 20, Addendums I and II and Glossary" (v6, December 2017). South Africa's own GMP document (SAHPGL-INSP-02, currently v9, 17 November 2025, 23 pages) now contains only:

• an Introduction (purpose/scope, largely restating PIC/S language),
• a Legal Provision section formally adopting the PIC/S Guide under South African law,
• a Regulatory Processes section (SAHPRA's reliance/recognition pathway for GMP certificates issued by other regulators),
• a South-Africa-specific "Annex 16" (a different, locally-authored document also called Annex 16, not to be confused with PIC/S's own Annex 16 on Authorised Person certification/batch release — see the naming-collision warning below) covering Organisation & Personnel, built around South Africa's distinctive statutory role of the Responsible Pharmacist,
• References, Validity, and two Appendices (recognised regulators for reliance; dosage-form/product-type/activity groupings for reliance applications).

Practical consequence for Regscribe's scoring logic: a document-analysis pass on a South African drug manufacturing site cannot cite "SAHPRA Chapter 4" or "SAHPRA Annex 11" the way the EU GMP rubric cites EU GMP Vol. 4 chapters — the actual substantive requirement text lives in the PIC/S PE 009 Guide, which SAHPRA has adopted by reference in full, including "all prospective adaptations as prescribed by the PIC/S" (SAHPGL-INSP-02 v9, §2.1). Because EU GMP Vol. 4 and PIC/S PE 009 are near-identical in structure and substance (PIC/S PE 009 and EU GMP Vol. 4 evolved in lockstep and share chapter/annex numbering for most of the document), this project's existing docs/gmp-gdp-rubric.md rows are the correct proxy for South Africa's PIC/S-adopted substantive chapters — this document does not re-derive them. What this document adds are the parts that are genuinely South Africa-specific: the statutory licensing basis under Act 101 of 1965, the Responsible Pharmacist regime (with no EU/US GMP analogue), the GMP-reliance pathway, and the two-tier PIC/S-Annex-16-vs-SA-Annex-16 naming collision.

Naming collision, flagged explicitly: PIC/S PE 009 Annex 16 ("Certification by the Authorised Person and Batch Release," added PE 009-16, in force 1 February 2022) and SAHPRA's own, locally-drafted "Annex 16 — South African Specific Requirements" (Organisation & Personnel / Responsible Pharmacist) are two completely different documents that happen to share a number. SAHPRA's guideline resolves this explicitly: "Annex 16 of the PIC/S guide to GMP pertains to country specific requirements and should be replaced with the SA specific Annex 16 as detailed in Section 4 of this guideline" (SAHPGL-INSP-02 v9, §2.1). In other words, PIC/S structurally reserves the "Annex 16" slot for each member's own national-requirements annex, and South Africa's national annex happens to be about Responsible Pharmacist/personnel matters rather than Authorised-Person batch-release certification (the topic PIC/S's own drafters used the slot for at the multinational level before national annexes were common). A document-analysis tool must not confuse a South African site's "Annex 16" evidence with the PIC/S batch-release-certification annex — check which Annex 16 a given citation actually refers to.

Sources used

Regulatory text (primary, current, fetched and read in full this session):

• SAHPGL-INSP-02_v9 — "Guidelines to Good Manufacturing Practice for Medicines," effective 17 November 2025, 23 pages — fetched directly from https://www.sahpra.org.za/wp-content/uploads/2025/11/SAHPGL-INSP-02_v9-Guidelines-to-Good-Manufacturing-Practice-for-Medicines.pdf (linked from SAHPRA's own document page, sahpra.org.za/document/sa-guide-to-good-manufacturing-practice-for-medicines/). This is a clean, text-layer PDF (unlike the scanned Japan Ordinance PDF in the companion rubric) — extracted with pdftotext -layout and read in full (all 23 pages, ~1,000 lines). This is the single primary source underlying every SAHPRA-specific citation in this document — the full Document History table (versions 1 through 9, 1997–2025), the complete Section 2 legal-adoption text, the complete Section 4 "Annex 16" Organisation & Personnel content, and the complete Appendix 1/2 reliance-pathway content were all read verbatim, not summarized from a secondary source.
• SAHPGL-INSP-GMP-02_v1 — "Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients," effective 27 October 2025 — fetched from https://www.sahpra.org.za/wp-content/uploads/2025/10/SAHPGL-INSP-GMP-02_v1-Good-Manufacturing-Practice-Guide-for-Active-Pharmaceutical-Ingredients.pdf, also a clean text-layer PDF, extracted and read in full (2,421 lines including the reproduced ICH Q7 text). This document states SAHPRA "wholly adopts" ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) as its API GMP standard, reproduces the full ICH Q7 text (Sections 1–20, matching ICH Q7's own numbering), and explicitly states SAHPRA's own SAHPGL-INSP-02 guideline takes precedence over ICH Q7 in case of conflict. This is the SA-specific analogue to EU GMP Part II / 21 CFR 211's implicit API coverage, and is structurally the same "wholesale adoption of an external, non-SAHPRA-drafted standard" pattern as the main GMP guideline's PIC/S adoption.
• PIC/S PE 009 Guide to GMP — not independently re-fetched/re-read in full this session (it is the subject of the companion docs/gmp-gdp-rubric.md, which sources EU GMP Vol. 4 — the near-identical sibling text). Version/currency confirmed via WebFetch of PIC/S's own news pages: PE 009-16 entered into force 1 February 2022 (added the country-specific-requirements Annex 16 slot and a revised Annex 13 for investigational medicinal products, aligned to EU Regulation 536/2014); PE 009-17 is current as of the most recent PIC/S news item found (an August 2023 entry-into-force notice for a fully rewritten Annex 1 on sterile manufacturing, itself aligned to the EU GMP Annex 1:2023 rewrite already modeled in this project's docs/eu-annex1-rubric.md). PIC/S's own site (picscheme.org/en/news/...) was used for version/date confirmation only — the PIC/S PE 009 chapter/annex body text itself was not independently re-fetched this session, since this project's EU GMP rubric already models that near-identical substantive text and re-deriving it here would duplicate rather than add value. Flagged as a residual gap below: PIC/S PE 009's own numbering could in principle have drifted slightly from EU GMP Vol. 4's numbering by PE 009-17, and this was not clause-by-clause diffed this session.
• Medicines and Related Substances Act, 1965 (Act 101 of 1965) — not independently fetched as a standalone statute this session; every specific section number cited below (22C(1)(b), Regulation 23, 22A(9)(a)(i)) is sourced directly from its verbatim quotation inside the two primary SAHPRA PDF sources above, not from an independent statute fetch. Both SAHPRA documents quote the same Section 22C(1)(b)/Regulation 23 licensing language almost word-for-word, which is treated as strong internal cross-confirmation. The Act's full text was not independently read this session — flagged below as a gap if a future pass needs to cite provisions beyond licensing (e.g., the Act's own definitions, offences, or the SAHPRA-establishment provisions).
• Pharmacy Act, 1974 (Act 53 of 1974) and its regulations (GNR 1160 of 20 November 2000) — cited only as quoted verbatim inside SAHPGL-INSP-02 v9 §4.1.2–4.1.3 (definitions of "responsible pharmacist," "manufacturing pharmacy," "direct/indirect personal supervision," Regulation 24/25). Not independently fetched from a Pharmacy Council or gov.za source this session — flagged below.

Institutional history (SAHPRA replacing the Medicines Control Council):

• Confirmed via WebSearch across multiple independent, consistent secondary sources (Spotlight NSP — a South African health-journalism outlet with direct sourcing to SAHPRA/Department of Health officials; Frontiers in Pharmacology academic review; Freyr Solutions regulatory-affairs summary; Wikipedia): SAHPRA officially commenced operations 1 February 2018, replacing both the Medicines Control Council (MCC) and the Directorate of Radiation Control (DRC), following 2017 amendments to Act 101 of 1965. SAHPRA inherited a backlog described by these sources as approximately 16,000 pending regulatory applications from the MCC, and a stated objective of the reform was to fix "slow regulatory decision times... and a culture of non-transparency." This is treated as high-confidence background — the 2018 date and MCC-to-SAHPRA transition are consistently reported across independent sources with no contradiction found — but no single primary Department of Health or SAHPRA-published transition document was independently fetched this session. Document-currency implication, flagged explicitly: because SAHPRA only came into existence in 2018, any GMP-related source dated before 2018 (e.g., an archived "Medicines Control Council" GMP guide, several of which surfaced in search results, including a June 2010 MCC-branded "SA Guide to GMP" still hosted at pharmcouncil.co.za) reflects the predecessor regulator and should not be treated as SAHPRA's current position — flagged so a future session doesn't accidentally cite an MCC-era document as current SAHPRA guidance. This rubric relies exclusively on 2025-dated SAHPRA-branded PDFs for its substantive citations.

Enforcement / failure-pattern data:

• Citro-Soda recall — Adcock Ingram, Clayville (Gauteng) facility, 2026 — the single best-documented, most current, most directly on-point real SAHPRA GMP enforcement example found this session. Confirmed across multiple independent South African news sources (SAnews.gov.za — the official South African government news service; Engineering News; Sowetan; The Mercury; ECR; HealthcareMEA) that are consistent with each other on the core facts: SAHPRA inspected Adcock Ingram's Clayville, Gauteng production facility in February 2026, identified critical GMP deficiencies, and on 20 March 2026 announced a recall of Citro-Soda Regular (60g, 120g, and 4g×30-sachet presentations, batch numbers starting with "C," manufactured April 2024–December 2025), sold in South Africa and exported to nine other African countries; SAHPRA held a public media briefing on 24 March 2026. The Engineering News report quotes SAHPRA's inspectorate head describing the specific findings verbatim: "metallic and black residue on equipment, posing a risk of contamination of the product"; "the absence of a suitable air handling system"; "ineffective and inconsistent cleaning procedures"; and "damaged, rusted and poorly maintained equipment." SAHPRA stated the metal fragments originated from the manufacturing vessels used to produce the product, that no adverse consumer reactions had been reported, and that it would "continue to monitor the implementation of actions" by Adcock Ingram — no manufacturing-licence suspension was reported in any source found this session (flagged as a gap: it is unclear whether SAHPRA imposed a formal licence action, a lesser corrective-action order, or relied solely on the recall + monitoring commitment). The unaffected Citro-Soda Cranberry variant is manufactured in Bangalore, India, and was explicitly excluded from the recall. This is marked [REPRESENTATIVE] below — it is a real, current, well-sourced, named SAHPRA enforcement action with verbatim regulator-quoted deficiency language, but it was sourced from South African news media covering a SAHPRA media briefing, not from a primary SAHPRA-published inspection report or formal notice-of-noncompliance document (no such primary document was located/fetched this session — SAHPRA does not appear to publish full inspection reports publicly the way, e.g., FDA warning letters are published).
• No SAHPRA-published aggregate GMP inspection-deficiency dataset (i.e., nothing analogous to MHRA's published GMP Inspection Deficiency Data Trend reports used in the companion gmp-gdp-rubric.md, or to FDA's CGMP inspectional-observation frequency data) was found this session. This appears to be a genuine transparency gap rather than a search failure — SAHPRA's public-facing enforcement communication this session consisted of ad hoc recall/media-briefing announcements (the Citro-Soda case), not a structured, citable deficiency-frequency publication. Flagged in Gaps below.
• No older/historical South African GMP scandal analogous to the EU thalidomide-era or Japan's Kobayashi Kako case was independently identified and verified this session. WebSearch surfaced general references to "well-documented API/finished-product quality issues in the SADC region" as a research prompt, but this session did not verify a specific, named, primary-sourced historical South African (as opposed to broader-SADC or non-SA-specific) case beyond the current Citro-Soda matter. This is flagged as [UNVERIFIED — flagged, not used] — rather than fabricate a historical enforcement narrative to parallel the other rubrics' [HISTORICAL] markers, this document uses only the one real, current, well-sourced case actually found.

Rubric legend

Each row: Requirement (plain language) → Citation → Evidence that demonstrates compliance → Common failure pattern

Failure-pattern cells are marked:

• [REPRESENTATIVE] — the real, confirmed, currently-reported Citro-Soda/Adcock Ingram case (2026), sourced via consistent South African news coverage of a SAHPRA media briefing rather than a primary SAHPRA-published inspection/enforcement document; or a well-established GMP failure mode drawn from the PIC/S/EU-GMP structural cross-reference already established in the companion gmp-gdp-rubric.md.
• [ANALOGOUS] — a failure pattern documented under PIC/S/EU GMP (via the companion rubric) that is structurally identical to what a South African PIC/S-adopting site would be scored against, but was not itself a South African enforcement action.
• [UNVERIFIED — flagged, not used] — a claim (chiefly: any historical South African GMP scandal predating 2026, and the exact current manufacturing-licence status of the Adcock Ingram facility) that could not be independently verified this session and is therefore not used to support any requirement row below.
• No [HISTORICAL] marker is used in this document in the sense the companion rubrics use it (a founding-era scandal that directly motivated the rule's creation) — this session did not verify a South-Africa-specific origin story for the 1965 Act or SAHPRA's GMP guideline; South Africa's GMP requirement instead derives its substance entirely from importing PIC/S's (EU-descended) framework, whose own founding history is already covered in the companion gmp-gdp-rubric.md.

SECTION 1 — Legal basis and licensing (South Africa–specific; no direct PIC/S/EU-GMP-text analogue)

SECTION 2 — Adoption of the PIC/S GMP Guide (the substantive GMP framework)

SECTION 3 — API GMP (ICH Q7, wholly adopted)

SECTION 4 — "Annex 16": South African-Specific Requirements — Organisation & Personnel

(This is SAHPRA's own, locally-drafted content — not sourced from PIC/S/EU GMP at all. It is the part of this rubric with the least overlap with the companion EU/US/Japan/China rubrics, built around the Responsible Pharmacist's dual accountability to SAHPRA (Medicines Act) and the Pharmacy Council (Pharmacy Act).)

SECTION 5 — Regulatory reliance / GMP-certificate-recognition pathway (South Africa–specific)

Cross-reference: South Africa (SAHPRA/PIC/S) vs. EU GMP (Vol. 4) vs. 21 CFR 210/211 vs. Japan GMP Ordinance

Recommendation: extend this project's shared "Evidence Type" layer with South-Africa-specific tags — responsible_pharmacist_appointment, pharmacy_council_registration, gmp_reliance_five_factor_match, scheduled_substance_permit — rather than building a fifth parallel evidence taxonomy. The large majority of substantive GMP rows (Quality System, documentation, production, quality control, outsourcing, validation, change control, deviation handling) should route directly to the existing docs/gmp-gdp-rubric.md evidence types, since South Africa's own law incorporates that same PIC/S-descended text by reference; only the Section 1 (licensing), Section 4 (Responsible Pharmacist/personnel), and Section 5 (reliance pathway) rows above are genuinely new evidence-type territory.

Gaps / follow-ups before this goes into production scoring

1. PIC/S PE 009's chapter/annex text itself was not independently re-fetched and re-read this session. This rubric relies on the companion docs/gmp-gdp-rubric.md (sourced from EU GMP Vol. 4) as a proxy for PIC/S PE 009's substantive content, on the strength of the two guides' well-documented close alignment — but this was not clause-by-clause diffed this session. By PE 009-17, PIC/S's own numbering could in principle have drifted from EU GMP Vol. 4's numbering in ways not caught here. Recommend a dedicated follow-up session that fetches PIC/S's own PE 009-17 PDF directly from picscheme.org (a "Publications" page was referenced but not itself fetched) and spot-checks at least Chapters 1, 4, 5, 6, and Annex 1 against the EU GMP rubric's existing row citations before treating this rubric's Section 2 cross-references as clause-verified rather than lineage-verified.
2. The Medicines and Related Substances Act, 1965 (Act 101 of 1965) itself was not independently fetched as a standalone statute this session. Every specific section citation (§22C(1)(b), Regulation 23, §22A(9)(a)(i)) is sourced only from its quotation inside SAHPRA's own PDFs, not from a direct statute fetch (e.g., via the South African government's own legislation portal or a legal database). This is treated as reliable — both independent SAHPRA documents quote the same language nearly verbatim — but a production pass citing Act provisions beyond licensing (e.g., SAHPRA's own establishment provisions, offences beyond §22C, or definitions) would need a direct statute fetch first.
3. No SAHPRA-published aggregate GMP inspection-deficiency dataset was found, unlike the MHRA data grounding the companion EU GMP rubric. Every failure-pattern cell in Sections 1, 4, and 5 above is a structural/interpretive inference from the guideline's own text (plus the one Citro-Soda case), not a frequency-weighted finding. If Regscribe wants severity-weighting for South Africa-specific rows, treat rows 13 (Production/QA independence), 14–18 (Responsible Pharmacist chain), and 27 (reliance five-factor test) as reasoned high-consequence defaults, not empirically-derived weights.
4. The Citro-Soda/Adcock Ingram case (row 17, and the Sources section) is sourced from South African news media covering a SAHPRA public briefing, not from a primary SAHPRA-published inspection report or formal enforcement notice. No such primary document was located or fetched this session — it is unclear whether SAHPRA publishes formal GMP non-compliance notices the way FDA publishes warning letters, or whether ad hoc recall/media-briefing announcements are the primary public enforcement-transparency mechanism in South Africa. Recommend a follow-up session searching SAHPRA's own website directly (e.g., a dedicated "recalls" or "compliance actions" page, if one exists) for a primary-sourced version of this case, and for any other, older SAHPRA enforcement actions that could upgrade this rubric's currently single-case evidentiary base.
5. No verified historical South African GMP scandal (pre-2026) was found to parallel the [HISTORICAL] markers used in the companion GLP and Japan GMP rubrics. This is flagged as a genuine research gap, not a decision to omit — a founding-era or notably consequential historical case may well exist (South Africa has a long pharmaceutical-manufacturing history, and the MCC-era regulatory environment was, per multiple secondary sources, criticized for slow/opaque decision-making) but was not independently identified and verified this session. Do not backfill this gap with an invented or loosely-sourced case in a future session without the same primary/secondary sourcing rigor applied to Citro-Soda.
6. The exact current manufacturing-licence status of Adcock Ingram's Clayville facility was not confirmed — no source found this session stated whether SAHPRA imposed a formal licence suspension/restriction, or relied solely on the recall plus a stated intent to "continue to monitor." Flag this as an open item if the Citro-Soda case is used in any customer-facing context — do not characterize it as a "licence suspension" without further verification.
7. The Pharmacy Act, 1974 (Act 53 of 1965) and its regulations (GNR 1160 of 20 November 2000) were only read as quoted inside SAHPGL-INSP-02 v9, not independently fetched from the Pharmacy Council or a South African government legislation source. Any production use of the Responsible Pharmacist rows (14–20) that needs Pharmacy Act citations beyond what SAHPRA itself quoted should independently verify against a primary Pharmacy Council/gov.za source first.
8. The SAHPRA GMP guideline's own "Version 10" status is itself uncertain. One WebFetch summarization of SAHPRA's document-listing page reported a "Version 10, last updated 24 April 2026" — a claim this session could not independently corroborate: the actual PDF fetched and fully read this session (via direct download + pdftotext) is unambiguously Version 9, dated 17 November 2025, with a complete, internally consistent Document History table ending at v9. The "v10" claim may reflect a WebFetch summarization artifact (the tool reading a dynamic page element inaccurately) rather than a real newer version. This rubric is built entirely on the verified v9 PDF — flagged here so a future session checks sahpra.org.za/document/sa-guide-to-good-manufacturing-practice-for-medicines/ directly for a possible v10 release before treating v9 as current indefinitely.